Table 2.
Univariate and Multivariate Analysis Cox Proportional Hazard Models for Risk Factors of Post-transplant CMV Infection
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| Risk Factors | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Recipient age (per year) | 1.00 (0.98–1.03) | .798 | ||
| Male | 0.85 (0.47–1.53) | .580 | ||
| BMI (per unit), kg/m2 | 1.03 (0.96–1.10) | .401 | ||
| Low pretransplant CMV-specific humoral immunity (anti-CMV IgG titer <20 AU/mL) | 2.70 (1.21–6.05) | .016 | 2.98 (1.31–6.77) | .009 |
| Donor age (per year) | 1.03 (1.01–1.06) | .008 | 1.03 (1.01–1.06) | .005 |
| Deceased donor | 5.17 (1.85–14.45) | .002 | ||
| Cold ischemic time (per hour) | 1.07 (1.03–1.12) | .001 | 1.06 (1.02–1.10) | .002 |
| Surgical time (per hour) | 1.14 (0.97–1.33) | .104 | ||
| Second KT | 0.05 (<0.001–1734) | .572 | ||
| HLA mismatch of ≥3 | 0.92 (0.50–1.70) | .800 | ||
| PRA of ≥51% | 1.40 (0.55–3.54) | .482 | ||
| Pretransplant DFPP | 5.30 (1.28–21.91) | .021 | ||
| Pretransplant IVIG | 3.48 (0.48–25.27) | .218 | ||
| Induction therapy | ||||
| ATG | 3.08 (1.20–7.95) | .020 | 2.90 (1.09–7.74) | .033 |
| Anti-IL-2 receptor antagonist | 0.99 (0.52–1.88) | .970 | ||
| Maintenance therapy | ||||
| Tacrolimus | 0.55 (0.30–1.02) | .056 | ||
| Cyclosporin A | 1.84 (1.00–3.40) | .049 | ||
| Mycophenolate mofetil | 1.45 (0.51–2.56) | .742 | ||
| Reoperation | 0.47 (<0.001–65.39) | .408 | ||
Abbreviations: ATG, antithymocyte globulin; AU, arbitrary unit; BMI, body mass index; CMV, cytomegalovirus; DFPP, double-filtration plasmapheresis; HLA, human leukocyte antigen; IgG, immunoglobulin G; IL, interleukin; IVIG, intravenous immunoglobulin; KT, kidney transplant; PRA, panel reactive antibody.